ArticleModern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc2018
Progression and regression of fibrosis in viral hepatitis in the treatment era: the Beijing classification.
Article in Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 53 citations in OpenAlex.
- Comparison of fibrosis regression of entecavir alone or combined with pegylated interferon alpha2a in patients with chronic hepatitis B.Hepatology international · 2021Trial
- Inflammation remains a dynamic component of portal hypertension in regressive alcohol-related cirrhosis.United European gastroenterology journal · 2025Observational
- Non-invasive assessment of portal hypertension: Liver stiffness and beyond.JHEP reports : innovation in hepatology · 2025Review
- Delicate and thin fibrous septa indicate a regression tendency in metabolic dysfunction-associated steatohepatitis patients with advanced fibrosis.Hepatology international · 2025Observational
- Liver fibrosis showed a two-phase regression rate during long-term anti-HBV therapy by three-time biopsies assessments.Hepatology international · 2024Article
- Three-dimensional analysis of ductular reactions and their correlation with liver regeneration and fibrosis.Virchows Archiv : an international journal of pathology · 2024Article
- A review of liver fibrosis and cirrhosis regression.Journal of pathology and translational medicine · 2023Review
- Quantitative image-based collagen structural features predict the reversibility of hepatitis C virus-induced liver fibrosis post antiviral therapies.Scientific reports · 2023Article
- [Histological regression and clinical benefits in patients with liver cirrhosis after long-term anti-HBV treatment].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- [Reversal of hepatic fibrosis: more evidence and more challenges].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- [Self-awareness rate and its influencing factors of their infection status among hepatitis B surface antigen-positive persons aged 15-69 years in China].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022Article
- What Makes Cirrhosis Irreversible?-Consideration on Structural Changes.Frontiers in medicine · 2022Article
- Regression of Hepatic Fibrosis and Evolution of Cirrhosis: A Concise Review.Advances in anatomic pathology · 2021Review
- Thick Fibrous Septa on Liver Biopsy Specimens Predict the Development of Decompensation in Patients With Compensated Cirrhosis.American journal of clinical pathology · 2021Article
- Liver Pathologic Changes After Direct-Acting Antiviral Agent Therapy and Sustained Virologic Response in the Setting of Chronic Hepatitis C Virus Infection.Archives of pathology & laboratory medicine · 2021Article
- Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.World journal of gastroenterology · 2021Article
- Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspective.Clinical and molecular hepatology · 2021Review
- Evolution of the liver biopsy and its future.Translational gastroenterology and hepatology · 2021Review
- Quantification of liver function using gadoxetic acid-enhanced MRI.Abdominal radiology (New York) · 2020Review
- An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials.Diagnostics (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this new era of successful long term suppression of hepatitis B viral replication and consistent eradication of hepatitis C virus the necessity for routine pre-treatment biopsies has often been eliminated. Thus, whether there is utility to perform liver biopsy in chronic viral hepatitis is undergoing re-examination. In response to these changing needs, we have developed a new staging system, the Beijing Classification, for assessment of biopsy specimens from patients with chronic viral hepatitis. The most important novelty of the Beijing Classification is that it includes not only extent (stage) of fibrosis, but the quality of fibrosis, namely if the specimen shows predominantly regressive vs. progressive features (or is indeterminantly balanced between the two), the P-I-R score. This histologic distinction between regressive and progressive fibrosis, while invoked in this particular setting of chronic viral hepatitis, may have applicability to all forms of chronic liver disease. Thus, the review contains a description of the concepts of regression and progression with the aim of empowering pathologists to apply them in histopathologic-clinical correlation research as well as in the specific clinical setting for which it was developed. Also, in light of changing clinical needs, grading of necroinflammatory activity and staging of fibrosis are simplified into three point scales. These simplifications should aid the general diagnostic pathologist in being comfortable and confident in assessing biopsy specimens as the criteria for their distinction are far more precise, with significantly reduced "gray zones" of prior grading/staging systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.